Patients with congestive heart failure (CHF) represent one of the largest groups in which loop diuretics are a mainstay of treatment. Their proper use requires an understanding of the mechanisms of response to diuretics in such patients. Over the past few years information has increased concerning the pharmacokinetics and pharmacodynamics of loop diuretics in various diseases but particularly CHF. These data have in turn allowed a more rational design of therapeutic regimens. This review discusses our current understanding of mechanisms of resistance to loop diuretics in patients with CHF and shows how such understanding dictates therapeutic strategy.
Bioavailability in patients and controls
As patients with CHF have peripheral oedema, it is not difficult to imagine how there might also be oedema of the intestinal wall that could impair absorption of loop diuretics and other drugs.'2 This issue has been examined in several oedematous disorders but particularly in CHF. One case report found that a patient with idiopathic oedema seemed to malabsorb furosemide3; however, studies in CHF-9 and in cirrhosis'0 have indicated that bioavailability is normal in oedematous disorders. Importantly, this is the case in patients who have both compensated and decompensated CHF7 and in cirrhotic patients both with and without ascites.'0 Thus malabsorption cannot be a mechanism for diuretic resistance in patients with CHF.49 Detailed studies in patients with both compensated and decompensated CHF Time (h) give larger doses than this is unlikely to produce any increase in efficacy and only risks toxicity in patients with CHF. This question has probably not been pursued ie right to a greater extent because acetazolamide causing could only be given for short periods to ed, but patients with CHF, until the metabolic acidosodium sis that occurred secondary to the drug ) about became limiiting. Clinicans should remember, )atients however, that in patients who are in critical it some need of diuresis, it is rational to consider use ally flat of acetazolamide in an attempt to cause diurematter sis when other methods of treatment have urinary failed. ,sue. If
Many publications describe the addition of iciency, thiazide diuretics to loop diuretics, the usual deliver result being a synergistic response. 13 It also seems that even more distal nephron sites can contribute to the blunted response to a loop diuretic. Because these more distal nephron sites reabsorb sodium in exchange for potassium, one can easily determine whether or not such distal reabsorption is operative in individual patients. Urinary electrolytic determinations in settings of increased distal sodium reabsorption will show low sodium concentrations but raised potassium concentrations.2627 In contrast, if the mechanism of decreased response to the loop diuretic is increased sodium reabsorption proximal to these sites, both sodium and potassium concentrations in the urine will be low. If one finds raised urinary potassium concentrations, addition of a potassium retaining diuretic should be considered, the dose of which can be titrated based on excretion of urinary electrolytes.2627
In conclusion diuretic resistance in patients with CHF is mostly due to pharmacodynamic factors that seem to be partly related to increased reabsorption of solute in other parts of the nephron. This mechanism explains the rationale for combinations of diuretic drugs in such patients as opposed to increasing doses of loop diuretics themselves. Understanding the mechanisms by which diuretic resistance occurs in patients ,with CHF has allowed design of appropriate dosing regimens of these drugs and rational use of combinations of diuretics. The overall result is improved patient care and the ability to produce a desired natriuretic response in nearly all patients.
